Aquestive Therapeutics, Inc. (AQST) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 16.48M USD | Liabilities, Current |
| Cash and equivalents | 98.49M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 7.37M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $16.48M | $98.49M | (m) | (m) | $7.37M | (m) |
| 2026-03-31 | (m) | $31.75M | $110.73M | (m) | (m) | $8.07M | (m) |
| 2025-12-31 | (m) | $47.61M | (m) | (m) | (m) | $6.17M | (m) |
| 2025-09-30 | (m) | $25.57M | $129.06M | (m) | (m) | $7.88M | (m) |
| 2025-06-30 | (m) | $23.16M | $60.54M | (m) | (m) | $8.13M | (m) |
| 2025-03-31 | (m) | $18.30M | $68.66M | (m) | (m) | $7.20M | (m) |
| 2024-12-31 | (m) | $18.86M | (m) | (m) | (m) | $6.04M | (m) |
| 2024-09-30 | (m) | $15.15M | $77.89M | (m) | (m) | $7.02M | (m) |
| 2024-06-30 | (m) | $13.89M | $89.87M | (m) | (m) | $6.97M | (m) |
| 2024-03-31 | (m) | $18.06M | $95.20M | (m) | (m) | $7.73M | (m) |
| 2023-12-31 | (m) | $18.31M | (m) | (m) | (m) | $6.77M | (m) |
| 2023-09-30 | (m) | $24.06M | $24.92M | (m) | (m) | $7.08M | (m) |
| 2023-06-30 | (m) | $38.65M | $22.44M | (m) | (m) | $5.95M | (m) |
| 2023-03-31 | (m) | $40.38M | $26.88M | (m) | (m) | $6.98M | (m) |
| 2022-12-31 | (m) | $39.53M | (m) | (m) | (m) | $5.78M | (m) |
| 2022-09-30 | (m) | $36.56M | $18.65M | (m) | (m) | $6.72M | (m) |
| 2022-06-30 | (m) | $29.64M | $17.70M | (m) | (m) | $5.01M | (m) |
| 2022-03-31 | (m) | $24.18M | $14.74M | (m) | (m) | $4.63M | (m) |
| 2021-12-31 | (m) | $21.96M | (m) | (m) | (m) | $4.04M | (m) |
| 2021-09-30 | (m) | $25.04M | $31.16M | (m) | (m) | $2.86M | (m) |
| 2021-06-30 | (m) | $23.04M | $34.23M | (m) | (m) | $2.84M | (m) |
| 2021-03-31 | (m) | $20.05M | $27.50M | (m) | (m) | $2.80M | (m) |
| 2020-12-31 | (m) | $21.10M | $31.81M | (m) | (m) | $2.46M | (m) |
| 2020-09-30 | (m) | $18.37M | $17.06M | (m) | (m) | $3.24M | (m) |
| 2020-06-30 | (m) | $14.88M | $25.42M | (m) | (m) | $3.17M | (m) |
| 2020-03-31 | (m) | $15.36M | $35.52M | (m) | (m) | $3.09M | (m) |
| 2019-12-31 | (m) | $18.55M | $49.33M | (m) | (m) | $2.86M | (m) |
| 2019-09-30 | (m) | $20.05M | $20.91M | (m) | (m) | $4.12M | (m) |
| 2019-06-30 | (m) | $24.63M | $22.16M | (m) | (m) | $4.65M | (m) |
| 2019-03-31 | (m) | $29.64M | $39.93M | (m) | (m) | $5.14M | (m) |
| 2018-12-31 | (m) | $32.95M | $60.60M | (m) | (m) | $5.44M | (m) |
| 2018-09-30 | (m) | $21.33M | $63.98M | (m) | $7.45M | $4.48M | (m) |
| 2018-06-30 | (m) | $23.47M | $10.64M | (m) | $6.63M | $4.35M | (m) |
| 2017-12-31 | (m) | $15.35M | $17.38M | (m) | $6.18M | $4.01M | (m) |
| 2017-09-30 | (m) | (m) | $25.44M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $10.29M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $9.21M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |